Kwikaton (Vildagliptin)

Vildagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises the levels of the incretin hormones GLP‑1 and GIP, which enhance glucose‑dependent insulin secretion and suppress glucagon release after meals, thereby lowering blood glucose without causing significant hypoglycaemia.

The dosage of Kwikaton is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal function, and response to therapy. Patients should follow the dose and administration schedule provided by their prescriber and not adjust the dose on their own.

Safety of vildagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Kwikaton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Kwikaton (vildagliptin) shares the same class mechanism as other DPP‑4 inhibitors like sitagliptin and saxagliptin, providing glucose‑dependent insulin release. Differences may exist in dosing frequency, renal adjustment requirements, and specific safety profiles; the choice of agent is usually guided by individual patient factors and prescriber preference.

Kwikaton should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Kwikaton is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

The most serious adverse reactions reported with vildagliptin include pancreatitis, severe allergic responses such as angioedema or Stevens‑Johnson syndrome, and significant hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of liver dysfunction while using the medication.

Kwikaton is contraindicated in patients with a known hypersensitivity to vildagliptin or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled heart failure, or a history of pancreatitis, and it should be avoided in pregnancy unless clearly justified by a physician.